## LUD 5466.4 CIP - JEL/NDH

Now only claims 89-95 are pending. Claim 89 is corrected. Thus, the issues set forth in the advisory action are addressed.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.F

Norman D. Hanson, Esq. Registration No. 30,946

666 Fifth Avenue New York, New York 10103-3198

Telephone: 212-318-3168 Telecopier: 212-318-3400

	Application No.	Applicant(s)
Advisory Action	09/165,546	ALEXANDER ET AL.
	Examiner	Art:Unit
	Amy M. DeCloux	1644
-The MAILING DATE of this communication ap	pears on the cover sheet with the	correspondence address
THE REPLY FILED 24 July 2002 FAILS TO PLACE THE Therefore, further action by the applicant is required to final rejection under 37 CFR 1.113 may only be either: condition for allowance; (2) a timely filed Notice of Appelexamination (RCE) in compliance with 37 CFR 1.114.	avoid abandonment of this applic (1) a timely filed amendment whic	ation. A proper reply to a th places the application in
•	REPLY [check either a) or b)]	
<ul> <li>a) The period for reply expires 6 months from the mailing d</li> <li>b) The period for reply expires on: (1) the mailing date of this no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY W. 706.07(f).</li> </ul>	s Advisory Action, or (2) the date set forth the later than SIX MONTHS from the mallin AS FILED WITHIN TWO MONTHS OF T	ng date of the final rejection. HE FINAL REJECTION. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the periodice under 37 CFR 1.17(a) is calculated from: (1) the expiration date (2) as set forth in (b) above, if checked. Any reply received by the C timely filed, may reduce any samed patent term adjustment. See 37 timely filed.	d of extension and the corresponding amoust of the shortened statutory period for reply office later than three months after the ma	ount of the fee. The appropriate extension or originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellan 37 CFR 1.192(a), or any extension thereof (37 C	t's Brief must be filed within the p FR 1.191(d)), to avoid dismissal o	eriod set forth in of the appeal.
2. The proposed amendment(s) will not be entered	because:	•
(a) X they raise new issues that would require furt	ther consideration and/or search (	see NOTE below);
(b) they raise the issue of new matter (see Note	e below);	
(c) they are not deemed to place the application issues for appeal; and/or	n in better form for appeal by mate	erially reducing or simplifying the
(d) they present additional claims without cance	eling a corresponding number of	finally rejected claims.
NOTE: See Continuation Sheet.		
<ol><li>Applicant's reply has overcome the following reje</li></ol>	ction(s):	
4. Newly proposed or amended claim(s) 89-91 and samendment canceling the non-allowable claim(s		I in a separate, timely filed
5. The a) affidavit, b) exhibit, or c) request f application in condition for allowance because:	or reconsideration has been cons	idered but does NOT place the
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	ecause it is not directed SOLELY	to Issues which were newly
7. For purposes of Appeal, the proposed amendme explanation of how the new or amended claims		
The status of the claim(s) is (or will be) as follows	s:	: :
Claim(s) allowed: 84 and 88.		
Claim(s) objected to: <u>76,77,79-81 and 86</u> .		
Claim(s) rejected: 74,75,78,85 and 87.		·
Claim(s) withdrawn from consideration: 6-8,11-13	3.16-54 and 61-73.	
8. The proposed drawing correction filed on	is a)□ approved or b)□ disapp	proved by the Examiner.
9. Note the attached Information Disclosure Statem	ent(s)( PTO-1449) Paper No(s).	· •
10.⊠ Other: See Continuation Sheet		
. •		

## Continuation Sheet (PTO-303)

Application N . 009/165,546

Continuation of 2. NOTE: Newly proposed claim 92 recites "has" which the xamin r is reading as open ended and expands the scope of the correlative claims that were pending upon the issuance of the final rejection. Applicant questions how open ended could this claim be since it requires that the peptide bind to an MHC-Class II DR53 molecule. However, the examiner notes that the open language of inewly proposed claim 92 could encompass additional amin acids that would inhibit the binding of an amin acid of SEQ ID NO 8, 9 or 10 and also include additional amino acids that bind to an MHC-Class II DR53 molecule.

Furthermore, it is unclear whether the word "defined" in newly added claim 93 is to be interpretted as open or closed language.

Continuation of 10. Other: A proper response to a Final rejection includes the cancellation of non-elected claims...

PATRICK J. NOLAN, PH.D.

• name	Application No.	Applicant(s)	
	09/165,546	ALEXANDER ET AL.	
Advisory Action	Examiner	Art Unit	
	Amy M. DeCloux	1644	
The MAILING DATE of this communicati п арре	ars on the cover sheet with the c	orrespondence address	
THE REPLY FILED 21 August 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.			
PERIOD FOR REPLY [check either a) or b)]			
a) The period for reply expiresmonths from the mailing	g date of the final rejection.	the second secon	
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).			
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).			
1. A Notice of Appeal was filed on 1230. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.			
2. The proposed amendment(s) will not be entered because:			
(a) ⊠ they raise new issues that would require further consideration and/or search (see NOTE below);			
(b) ☐ they raise the issue of new matter (see Note below);			
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the			
issues for appeal; and/or			
(d) they present additional claims without canceling a corresponding number of finally rejected claims.			
NOTE: See Continuation Sheet.			
3. Applicant's reply has overcome the following rejection(s):			
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).			
5.☐ The a)☐ affidavit, b)☐ exhibit, or c)☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because:			
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.			
7 For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.			
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed:		· :	
Claim(s) objected to:			
Claim(s) rejected:			
Claim(s) withdrawn from consideration:			
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.			
9. Note the attached Information Disclosure Statemer	nt(s)( PTO-1449) Paper No(s)		
10. Other:			
		:	

U.S. Patent and Trademark Office

## Continuation Sheet (PTO-303)

**Application No. 09/165,546** 

Continuation of 2. NOTE: It is noted that applicant still has not addressed the rejection of claim 87 regarding its recitation of SEQ.ID NO:1, which is a nucleic acid (see the Final rejection mailed 3-14-02 (Paper No. 27)). It is noted that newly proposed base claim 89 and dependent claims 90-92 broad in the scope of claim 74 because claim 89 would not contain the limitation recited in claim 74 that the recited peptide stimulates recognition and proliferation of CD4+ cells, and thus claims 89-92 w uld reuire further consid ration and search. Similarly, n wly proposed claim 95 would also require further consideration and s arch, for the reasons just described. Further it is n ted that the second "an" in the first lin f newly proposed claim 89 should be deleted to be consistent with the plural noun it modifies Furth r it is noted that if claims 61-81 were cancelled, claims 85-87 would ultimately depend from a cancel d claim (claim 74). .

12/12/02